Generate a tailored SOP for Dr. Stephan Grupp. Improve your application with a focused, well-structured draft.
Stephan Grupp is a Professor in the Department of Pediatrics at the University of Pennsylvania and is an internationally recognized expert in CAR T cell therapy and pediatric transplant. He has extensive experience in the development and preclinical testing of engineered cell therapies and signal transduction inhibitors aimed at treating childhood leukemia. As the lead investigator for CTL019, he has been pivotal in pioneering clinical trials that led to the first approval of CAR T therapy for pediatric use. His research focuses on improving treatment outcomes for children with both malignant and non-malignant conditions, particularly through innovative applications of cell therapies. Grupp directs the Cancer Immunotherapy Frontier Program and oversees the clinical use of CAR T cells in hematopoietic stem cell transplantation. He is dedicated to changing standard care practices in the field, particularly through advanced research initiatives that encompass groundbreaking studies on cytokine release syndrome and the translational significance of the mTOR pathway in cancer treatment. Throughout his career, he has been involved in numerous major clinical trials and has contributed to seminal publications in prestigious journals, advancing the understanding and application of CAR T therapy in pediatric oncology.
Wharton Doctoral programs cover fields like Finance, Marketing, Management, and Operations, Information and Decisions.